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Flutamide: Dermatology and respect to
evidence and safety
Flutamida: a Dermatologia e o respeito às
evidências e à segurança
A clinical case that was carefully studied and
presented in this issue under the name of  "Flutamide
hepatotoxicity in a patient undergoing acne
treatment"* compels us to go into a series of
reflections.
This is about a heated and momentous issue,
which not only allows a specific analysis, but can also
give way to a transposition to another very frequent
situation in today's Dermatology.
Not only the dermatologist, but also the
medical class in general, is faced with the dilemma
between the merits and risks involved in the
prescription of drugs which are not approved by the
National Agency for Sanitary Surveillance (Anvisa). It
may be pleaded that when we limit ourselves to
prescribing only the drugs approved by the official
regulatory agencies, we retard, break the evolutional
process of therapeutics. At the same time, for others,
such prescriptions would be on the borderline
between medical malpractice and anti-ethical
attitudes.
In the specific case of flutamide, we have
important statements such as that of the Brazilian
Center of Drug Information, belonging to the Federal
Pharmacy Council: "studies that refer to the use of
flutamide do not display sufficiently consistent
results to advocate dermatological application. In the
opinion of this organ, further study is needed." In
several countries, flutamide is registered with the
exclusive indication for prostate cancer (USA, France,
Italy, Belgium, Canada, Turkey, Argentina,
Switzerland). In 1999, the laboratory that is
responsible for the product commercialization itself
published a letter addressed to health professionals,
through the World Health Organization, highlighting
the lack of studies in women and opposing  the use
of the drug in this population, mainly in affections
that carry no life-threatening risks. 
In Brazil, Anvisa issued a warning in
October 2004 recommending caution with  the use
of flutamide, due to case reports of fulminating
hepatitis associated to the use of this drug in
women. The agency decided to confirm prostate
cancer as the only approved indication and to
request notification of suspicion of any adverse
reaction, considering the cost/benefit relation
totally unfavorable to women. 
As said by Dr. Álvaro Atallah, one of the
worldwide references in Evidence-Based Medicine,
the great majority of drugs ends up receiving approval
in studies carried out, even when in large scale, in no
more than about 5,000 patients. A single death in this
sample can be interpreted as not related to the use of
the drug. What can happen when after
commercialization this correlation proves itself
positive in a population of millions of users? By the
way, remember the recent episodes surrounding anti-
inflammatory drugs.
Particularly in our midst, a few aggravating
issues must be considered, namely:
lack of proper clinical and laboratorial follow-
up by a considerable number of colleagues;
trivialization and vulgarization of the
indications, without due discussion about risks with
patients;
indication, by colleagues of various areas and
even by lay people, of the use of the medication;
inexistence of fulfillment, by drugstores, of
the mandatory presentation of medical prescription
for the acquisition of drugs, and precarious control by
official agencies;
 sale of the product by some pharmacies that
do not enforce the obligation to attach the
description, specifications and orientation on
product use, as well as warnings about possible side
effects.
*see pages 381-4
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We should not forget, either, to consider the
existing therapeutic weaponry, alternative to the use
of flutamide and which is the safety profile exhibited
by each of these drugs. 
We must keep on respecting the unstopping
search for the best for our patients, because they are
the reason for our being; hence there are no excuses
for sacrificing their safety in the quest for efficacy. 
Primo non nocere!
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